Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01854944 · ClinicalTrials.gov registry record · Phase 1
PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01854944 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 12 participants.
The verdict
NCT01854944, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how low and high does of brexpiprazole binds to certain receptors in the brain. This will be determined by PET scans taken pre-dose and post-dose.
Interventions
- DRUG Brexpiprazole 1mg to 4mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01854944
The ClinicalTrials.gov registry entry for NCT01854944 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brexpiprazole 1mg to 4mg is the first listed.
NCT01854944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01854944 about?
NCT01854944 is a clinical study titled "PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia". The purpose of this study is to determine how low and high does of brexpiprazole binds to certain receptors in the brain. This will be determined by PET scans taken pre-dose and post-dose.
What is the current status of trial NCT01854944?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-09. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01854944?
The interventions under investigation include: Brexpiprazole 1mg to 4mg (DRUG).
Who is sponsoring clinical trial NCT01854944?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.